Bioscope.ai Advances Personalized Longevity Medicine Through New Partnerships and Platform Growth

AI-powered precision longevity platform reports more than 450% ARR growth, more than 100% patient growth, and 65% growth in practice adoption, alongside new partnerships and expanded platform capabilities

CARMEL, Ind., Nov. 10, 2026 /PRNewswire/ -- Bioscope.ai, an AI platform for concierge and longevity physicians, is announcing significant growth in 2026, with annual recurring revenue (ARR) increasing more than 450%, its patient base growing by more than 100%, and the number of practices using its platform growing 65% since June 2026. As demand grows for tools that help physicians develop a more comprehensive view of each patient's health, the company is building on this momentum by expanding capabilities, forming new partnerships, and continuing to invest in its team.

"Concierge and longevity physicians already know how to practice medicine, and they have a method that's made them successful. It's why patients choose them. What they don't have is time to apply it across a whole genome, years of records and a stream of wearable data," said Don Brown, MD, founder and CEO of Bioscope.ai. "Our growth tells us physicians want AI that works the way they practice, not one that arrives with someone else's medicine already built in."

Furthering its mission to advance personalized, proactive healthcare, Bioscope has partnered with DNAvisit to connect physicians with genetic counseling in days rather than weeks. Through the partnership, physicians gain access to an expert second opinion on complex genetic findings, support in communicating difficult results to patients, and guidance on whether further testing may be appropriate for patients and their family members. The service is now integrated directly into Bioscope.ai's genomics workflow, so physicians can request counseling and receive responses within the platform.

Bioscope.ai is also investing in the people and technology needed to support this growth, increasing headcount by 37% since June 2026 with hires across marketing, sales and engineering. Recent senior leadership additions include Logan Mallory as chief marketing Officer and Jessica Sexton as vice president of customer success and operations. This year, the platform has continued to evolve with MRI-based brain volumetrics, expanded microbiome analysis that includes pathogen detection and antimicrobial-resistance markers, expanded pharmacogenomics analysis and updated polygenic risk scores.

Chief Medical Officer Dr. Helen Messier recently spoke at the Concierge Medicine Forum and in two sessions at the Eudēmonia Summit. She will continue the conversation at A4M's LongevityFest 2026, taking place December 11–13 in Las Vegas, where Bioscope.ai will exhibit at Booth 1073. Dr. Messier will also lead a hosted lunch on Friday, December 11, titled "What the Clocks Can't Tell You: The Genetic Time Bomb in Your Healthiest Patient," and speak during a session focused on AI on Saturday, December 12.

About Bioscope.ai

Bioscope.ai is a physician-founded precision longevity platform that helps longevity and concierge physicians deliver proactive, personalized care. Using AI to synthesize a patient's comprehensive medical history and genomic data, Bioscope.ai enables physicians to spend less time reviewing fragmented records and gain a more unified view of each patient's health to inform clinical decision-making. Designed to work within each physician's existing clinical approach and practice workflows, the platform supports more informed care planning while keeping clinical decisions in the physician's hands. Built with patient privacy and data security in mind, Bioscope.ai is HIPAA-compliant.

For more information, visit https://www.bioscope.ai.

SOURCE Bioscope.ai